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区手足口病发病率约为 1.19‰，男女比例为 1.65：1。年龄最小者 0.1岁，最大者
38岁，其中 0.5-4岁儿童占 88.9%。地区分布方面，厦门岛内送检样本占 62.87%，
岛外送检样本占 37.13%。主要流行时间为 4-8月。







EV71 B5亚型外，厦门地区流行的 EV71均可归入 C4亚型中的 a亚型。EV71在



































During the recent years, the incidence of hand, foot and mouth disease(HFMD)
in China is increasing, Severe cases and death in a corresponding increase, which
seriously harms the health of children. There is currently no vaccine and effective
treatment for HFMD, so the epidemiological investigation is particularly important.
In this study, an HFMD nRT-PCR detection sysytem is established, including three
sets of primers: whole EV, EV71 and CA16. Amplified segment is both conserved
and variable, which allows the evolutionary position to be determined by sequencing.
This can partly replace the traditional VP1 full-length sequencing. This system has
a good correlation compared with commerical regent. Study on the properties of this
method proved that it has good sensitivity, specificity and reproducibility, suitable
for the epidemiological surveillance of HFMD.
In this study, we investigated 5097 ambulatory cases and 75 severe cases, dating
from 2008 to 2011. It shows that the incidence rate of HFMD is 1.19‰in Xiamen,
2009. Gender ratio is 1.65: 1. Aging from 0.1 to 38 years old, the patients are
majorly 1-4 years old children. As about the regional distribution, Xiamen island
takes 62.87%, while outside Xiamen island takes 37.13%. The major epidemic time
is from April to August. Severe cases mainly appeared in May and June, when
HFMD was pandemic. The main symptoms are fever, rash, and convulsions.
On the pathogen spectrum monitoring of Xiamen HFMD, we discovered CA16 was
the primary enterovirus in Xiamen, 2009. EV71 was secondary. However, in 2010,
EV71 changed to be the primary, and CA16 was secondary. The rate of CA6 was
greatly incereased in the date from May to November. In 2011, CA6 became the
primary enterovirus, and EV71 was secondary. suspected recombination and co-















than other combinations. This could be associated with the fact that these two
viruses were the major epidemic strains. Besides, an EV71 B5 subtype strain was
discovered, which was the first discovery of EV71 B5 subtype in China mainland.
Molecular evolution analysis showed that the epidemic EV71 in Xiamen can be
classified as subtype a in subtype C4. It can be furtherly divided into three branches:
L1, L2 and L3. The ratio of L1 and L2 was decreasing by time, while the ratio of
L3 was increasing. It can be anticipated that L1 and L2 branches will gradually
become demise, and L3 will become the mayority in Xiamen. Evolutionary rate of
EV71 C4 subtype was 5.58 × 10−3 per site per year. Evolutionary divergence time
was about 1992. Theoretical infection quantity notability increased in 2008. It can
be predicted that the theoretical infection quantity would have a downtrend after
2010. The epidemic CA16 in Xiamen can be classified as subtype B1. It can be
furtherly divided into two branches: B1a and B1b. It can be predicted that the
two branches will have coexistence in future. Evolutionary rate of CA16 B subtype
was 9.507 × 10−3 per site per year. Evolutionary divergence time was about 1972.
Theoretical infection quantity was slowly increased from 1995, but no outbreak. The
epidemic CA6 in Xiamen can be divied into two branches, one close to Finland strain
and the other close to Japan strain. The two branches competed with each other,
there is currently no sign of any branch demise. The epidemic CA10 in Xiamen
has a close relationship with the Shandong strain GQ214173, but not close to other
Shandong strains, which indicated this strain might be the one firstly transmissed
to Xiamen. The epidemic CB3 in Xiamen has only one branch, which was the same
branch reported from other places in China, indicating it might by transmissed from
China inland.
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